Lattice Biologics Ltd., - CEO, Guy Cook
CEO, Guy Cook
Source: The Business Journals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lattice Biologics (TSXV:LBL) is recruiting patients for a clinical trial to determine how effective its AmnioBoost treatment is against COVID-19
  • The trial will test 10 patients in Seattle, who are experiencing COVID-related severe acute respiratory syndrome, against a placebo group
  • If no noticeable difference shows between the AmnioBoost and placebo groups, then Lattice will halt the treatment immediately
  • The AmnioBoost treatment is a stem-cell therapy, which is currently used to treat osteoarthritis
  • Lattice Biologics (LBL) is down 5.26 per cent, with shares trading for C$0.09 and a market cap of $8.41 million

Lattice Biologics (TSXV:LBL) is recruiting patients for a clinical trial, to determine how effectively its AmnioBoost treats COVID-19.

The company’s AmnioBoost treatment is a stem-cell therapy which uses amniotic fluid from human donors. It currently functions as a treatment for osteoarthritis.

Lattice hopes that the stem cell treatment could help coronavirus patients who contract severe acute respiratory syndrome.

With research still in its early stages, the proposed trial will help determine if there is cause for further testing. A relatively small phase one trial will test 10 coronavirus patients in Seattle. Seattle currently has one of the highest rates of infection in the United States.

Patients who have a laboratory-confirmed case of COVID-19 will be eligible to participate.

Those who are having severe symptoms and require oxygen or ventilators will receive two doses of the AmnioBoost treatment. The doctors treating these patients will monitor their vitals signs over a week, and compare them against a placebo group.

This should provide valuable data about the treatment’s efficacy against the coronavirus’s negative effects. If no noticeable difference shows between the AmnioBoost and placebo groups, then the company will halt the treatment immediately. 

Guy Cook, CEO of Lattice Biologics, is grateful to the trial’s participants. He also expressed his interest in seeing the early-stage trial’s results.

“We thank the patients in advance for their participation in this cost-free-to-the-patient trial.

“We look forward to using a novel technology in the treatment of this highly infectious disease and to make sure the trial is carried out in the most effective manner possible,” he said.

The company did not state when it expects to release the trial’s results to the public.

Lattice Biologics (LBL) is down 5.26 per cent, with shares trading for C$0.09 at 11:46am EST.

More From The Market Herald
Featured Video Play Icon

" Sixth Wave (CSE:SIXW) announces rapid detection of E. Coli

Sixth Wave’s (SIXW) AMIPs prototype has detected E. Coli in as little as five minutes.

" Neovasc (TSX:NVCN) announces direct sales operations in the U.K.

Neovasc (NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022.
Lexagene Holdings - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) to host a webinar on the use of the MiQLab system to diagnose urinary tract infections

 LexaGene Holdings (LXG) and Dr. Jane Sykes will present a webinar entitled, “The Wave of the Future: In-Clinic PCR Diagnosis.”
BriaCell Therapeutics Corp

" BriaCell (TSX:BCT) partners with Waisman Biomanufacturing

BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer.